Tezepelumab

特泽利尤单抗

Report date: 2026/05/07 20:00:36
First In Class

Base Information

Drug NameTezepelumab
Drug Alias NameTezepelumab-ekkoTezspireMEDI-9929AMG-157
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)AnaphylaxisHypersensitivity, Immediate +[19] 
Global Approved IndicationsAsthma
Approved Indications in ChinaAsthma
Original Approved Country/TerritoryUnited States
Original Approved Date2021/12/17
Country/TerritoryCzechiaBelgiumBulgaria +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstrazeneca Kk +[7] 
Inactive CompaniesUniversity Of Newcastle (Australia)University Of CopenhagenMedimmune Llc +[5] 
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic UrticariaNasal Polyps +[8] 
Inactive IndicationsAnaphylaxisHypersensitivity, ImmediateHypersensitivity +[11] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG